Neuronetics, Inc. (STIM): restructuring charge — Neuronetics announces CFO resignation, 5% workforce reduction, and former CEO consulting deal

Neuronetics, Inc.

Former CEO Keith J. Sullivan enters consulting agreement with release; will vest in equity through March 2027; no additional compensation.
CFO Steven E. Pfanstiel resigns effective May 1, 2026; company launches search for successor; no dispute.
Workforce reduction impacting up to 5% of employees; expects $0.2M restructuring charge in Q2 2026.
Annualized cost savings of $2.5M to $3.0M expected, primarily starting in Q3 2026.
Reaffirms FY2026 financial guidance provided during Q4 2025 earnings call on March 17, 2026.

item 1.01 item 2.05 item 5.02 item 7.01 item 9.01

Key facts

Extracted from this filing and checked against the source text.

Restructurings & Charges SEC 8-K Item 2.05/2.06 confidence 0.9

Neuronetics, Inc. announced a restructuring with charges of approximately $0.2 million (up to 5% of its employees).

Type: restructuring
Charge: approximately $0.2 million
Headcount: up to 5% of its employees

Exact text from the filing

On April 2, 2026, the Company initiated a workforce reduction, which it expects to be completed by mid-year 2026, that will impact up to 5% of its employees. The reduction is part of a broader effort to optimize the Company’s cost structure. The Company expects to incur restructuring charges of approximately $0.2 million, primarily for severance and related costs, in the second quarter of 2026.

View on SEC.gov

3 restructurings & charges filed in the last 30 days. Browse all restructurings & charges →

Neuronetics, Inc. filing history →

Source: SEC EDGAR

accession 0001193125-26-143876

view filing index on sec.gov

view primary document

Machine-readable: JSON · Markdown · Plain text

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.